Arrowhead shareholders reject advisory pay plan and director comp plan at annual meeting

ARROWHEAD PHARMACEUTICALS, INC.

Advisory vote on executive compensation: 54.8M against vs 14.2M for; proposal fails.
Non-Employee Director Compensation Plan: 52.5M against vs 16.0M for; proposal fails.
Three directors (Ferrari, Perry, Waddill) received majority AGAINST votes (44.4M, 39.8M, 42.7M resp.).
Ratification of auditors (Rose Snyder & Jacobs) passed with 87.2M votes for.
Approx. 20.2M broker non-votes on all proposals except auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.